HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $350 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $350 price target.

Last updated: 2026-11-19 02:29:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Revolution Medicines, Inc. (RVMD) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $159.76, with a market capitalization of $36.09B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $67.86 to $224.31. This page covers its latest market performance, valuation, price trends and company information.
$36.09B | |
$162.35 | |
$171.72 | |
$158.68 | |
$162.69 | |
1.79M | |
2.21M | |
-- | |
$224.31 | |
$67.86 | |
-- | |
2026-09-30 |
Revolution Medicines, Inc. (RVMD) last closed at $159.76 as of 2026-11-19 00:58:00, down 1.75% ($2.85) from the previous close of $162.69.
During the latest regular trading session, RVMD traded between $158.68 and $171.72, with a volume of 1.79M shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Revolution Medicines, Inc. (RVMD) moved from $200.15 to $159.76, representing a decline of 20.18% ($40.39).
The stock traded between $158.68 and $201.11 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.72 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 58.7%
RVMD is currently trading at $159.76, placing it 58.7% of the way from its 52-week low of $67.86 to its 52-week high of $224.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 883 |
| CEO | Mark A. Goldsmith |
| Founded | 2014 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Revolution Medicines, Inc. and RVMD stock.
HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $350 price target.
The European Commission has approved RASONQUE (daraxonrasib) by Revolution Medicines for treating adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The approval, based on positive Phase 3 RASolute 302 trial results, represents a significant advancement for pancreatic cancer treatment in the EU, with the company working to enable patient access through national pricing and reimbursement processes.
Morgan Stanley analyst Sean Laaman maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and lowers the price target from $272 to $247.
The FDA reportedly shelves its fast-track drug voucher pilot amid internal chaos, returning review oversight to career scientists.
Eligible investors can buy real shares of Revolution Medicines, Inc. (RVMD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to RVMD, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between RVMD shares and USD.
RVMD Shares to USD
1.00 RVMD shares = 159.764 USD
Calculations are estimates based on the latest available price and are for reference only.